Poor-prognosis gestational trophoblastic disease: an update

Area of Science:

• Oncology
• Gynecologic Oncology
• Chemotherapy

Background:

• Gestational trophoblastic neoplasia (GTN) with poor prognosis presents a significant clinical challenge.
• Metastatic disease, including brain and liver involvement, complicates treatment outcomes.

Purpose of the Study:

• To evaluate the efficacy of a modified Bagshawe chemotherapy regimen in patients with poor-prognosis GTN.
• To assess the toxicity profile of the chemotherapy regimen and surgical interventions.

Main Methods:

• Ten patients with poor-prognosis GTN received the modified Bagshawe regimen between 1979 and 1983.
• Combination chemotherapy included etoposide (VP-16), bleomycin, cisplatin, 5-fluorouracil, and cis-retinoic acid.
• Surgical procedures such as thoracotomy, hysterectomy, and splenectomy were performed for isolated resistant disease.

Main Results:

• Nine out of ten patients (90%) achieved complete remission, with follow-up ranging from 4 to 44 months.
• Significant myelosuppression occurred in seven patients, and two experienced life-threatening toxicity.
• Brain metastases were present in four patients, and one had liver metastases.

Conclusions:

• The modified Bagshawe regimen, often in combination with etoposide, bleomycin, and cisplatin, is effective for poor-prognosis GTN.
• Current treatment protocols involve alternating this regimen with etoposide, bleomycin, and cisplatin every other week.
• Careful monitoring for myelosuppression and toxicity is crucial during treatment.